Is It Time To Reassess Mineralys Therapeutics (MLYS) After The Recent Share Price Pullback? [Yahoo! Finance]
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: Yahoo! Finance
Wondering if Mineralys Therapeutics at a last close of US$23.28 still offers value, or if most of the easy gains are already behind it. The share price has seen a 13.7% decline over the past week and a 16.7% decline over the last 30 days, even though the 1 year return sits at 39.2% and the 3 year return at 50.8%. This mix of shorter term weakness and longer term gains can sometimes reflect shifting views on risk and potential, especially for a biotech where sentiment often turns quickly. While this article is not tied to a specific news headline, it aims to give context for those moves by focusing on what the current price might imply about expectations baked into the stock. Right now, Mineralys Therapeutics holds a value score of 3 out of 6 . The next sections will break down how different valuation approaches arrive at that result, before finishing with a framework that can help you interpret these methods together rather than in isolation. Mineralys Therapeutics delivered
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal OfficerGlobeNewswire
- R1 starts up with $78M, aiming for a better kidney drug [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mineralys Therapeutics (MLYS) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MLYS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sMarketBeat
- Mineralys Therapeutics (MLYS) had its "hold" rating reaffirmed by Jefferies Financial Group Inc..MarketBeat
MLYS
Earnings
- 3/12/26 - Beat
MLYS
Sec Filings
- 3/17/26 - Form 144
- 3/17/26 - Form 4
- 3/16/26 - Form 4
- MLYS's page on the SEC website